Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Since U.S. President Barack Obama announced the Precision Medicine Initiative in his New Year’s State of the Union address in 2015, the establishment of a precision medicine system has been emphasized worldwide, particularly in the field of oncology. With the advent of next-generation sequencers specifically, genome analysis technology has made remarkable progress, and there are active efforts to apply genome information to diagnosis and treatment. Generally, in the process of feeding back the results of next-generation sequencing analysis to patients, a molecular tumor board (MTB), consisting of experts in clinical oncology, genetic medicine, etc., is established to discuss the results. On the other hand, an MTB currently involves a large amount of work, with humans searching through vast databases and literature, selecting the best drug candidates, and manually confirming the status of available clinical trials. In addition, as personalized medicine advances, the burden on MTB members is expected to increase in the future. Under these circumstances, introducing cutting-edge artificial intelligence (AI) technology and information and communication technology to MTBs while reducing the burden on MTB members and building a platform that enables more accurate and personalized medical care would be of great benefit to patients. In this review, we introduced the latest status of elemental technologies that have potential for AI utilization in MTB, and discussed issues that may arise in the future as we progress with AI implementation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deep Residual Learning for Image Recognition
He, K., Zhang, X., Ren, S., & Sun, J. (2016) · 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR) · doi:10.1109/cvpr.2016.90 · Cited by 235,474
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
ClinVar: public archive of relationships among sequence variation and human phenotype
Landrum, M. J., Lee, J. M., Riley, G. R., Jang, W., Rubinstein, W. S., Church, D. M., & Maglott, D. R. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1113 · Cited by 3,516
Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J. (2022) · Nature Medicine · doi:10.1038/s41591-021-01614-0 · Cited by 3,212 · cited 1×
“Second, to date, medical image analysis has been the leading medical AI research and development method, and most AI-based medical device programs approved by the FDA are also targeted at medical image analysis [30, 31, 99, 180, 181].”
MethodBig data in healthcare: management, analysis and future prospects
Dash, S., Shakyawar, S. K., Sharma, M., & Kaushik, S. (2019) · Journal of Big Data · doi:10.1186/s40537-019-0217-0 · Cited by 1,747 · cited 1×
“Modern healthcare systems generate and store vast amounts of digital information and have great potential for personalizing and improving healthcare delivery [148, 149].”
BackgroundShickel, B., Tighe, P. J., Bihorac, A., & Rashidi, P. (2018) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2017.2767063 · Cited by 1,688
Medical image analysis using convolutional neural networks: a review
Anwar, S. M., Majid, M., Qayyum, A., Awais, M., Alnowami, M., & Khan, M. K. (2018) · Journal of Medical Systems · doi:10.1007/s10916-018-1088-1 · Cited by 1,431 · cited 1×
“In addition, since neighboring pixels tend to have similar information with respect to images, models such as convolutional neural networks, one of the deep learning techniques, are useful [185, 186].”
BackgroundThe Human Genome Project: Lessons from Large-Scale Biology
Collins, F. S., Morgan, M., & Patrinos, A. (2003) · Science · doi:10.1126/science.1084564 · Cited by 1,284
Benjamens, S., Dhunnoo, P., & Meskó, B. (2020) · npj Digital Medicine · doi:10.1038/s41746-020-00324-0 · Cited by 1,215 · cited 1×
“Second, to date, medical image analysis has been the leading medical AI research and development method, and most AI-based medical device programs approved by the FDA are also targeted at medical image analysis [30, 31, 99, 180, 181].”
Method
Cited by
Lukac, S., Dayan, D., Fink, V., Leinert, E., Hartkopf, A., Veselinovic, K., Janni, W., Rack, B., Pfister, K., Heitmeir, B., et al. (2023) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-023-07130-5 · Cited by 130
“The available reviews discussing AI in oncology premising a high burden of knowledge and information needed of persons in molecular tumor boards [16] and so the AI could improve this human’s limitations in order to Prompt Session 1 Scorer 1”
BackgroundHamamoto, R., Koyama, T., Takahashi, S., Yasuda, T., Kobayashi, K., Akagi, Y., Kouno, N., Sudo, K., Hirata, M., Sunami, K., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01781-y · Cited by 8
Self-citationDe la Torre-Trillo, J., Yáñez Castillo, Y., Melgarejo Segura, M. T., Carmona Sánchez, E., Zambudio Munuera, A., Mora-Delgado, J., & López Luque, A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062130 · Cited by 5
Metadata
- Authors
- Hamamoto, R., Koyama, T., Kouno, N., Yasuda, T., Yui, S., Sudo, K., Hirata, M., Sunami, K., Kubo, T., Takasawa, K., Takahashi, S., Machino, H., Kobayashi, K., Asada, K., Komatsu, M., Kaneko, S., Yatabe, Y., & Yamamoto, N.
- Venue
- Experimental Hematology & Oncology
- Published
- 2022-10-31
- Volume
- 11
- Issue
- 1
- Pages
- 82-82
- ISSN
- 2162-3619 (ISSN-L)
- OpenAlex
- W4307887190
- Cited by
- 48
- References
- 29
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information. https://app.cochat.ai/papers/10.1186/s40164-022-00333-7
- The paper
- Hamamoto, R., Koyama, T., Kouno, N., Yasuda, T., Yui, S., Sudo, K., Hirata, M., Sunami, K., Kubo, T., Takasawa, K., Takahashi, S., Machino, H., Kobayashi, K., Asada, K., Komatsu, M., Kaneko, S., Yatabe, Y., & Yamamoto, N. (2022). Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information. Experimental Hematology & Oncology. https://doi.org/10.1186/s40164-022-00333-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.